Core Viewpoint - A class action securities lawsuit has been filed against Rocket Companies, Inc. due to alleged securities fraud that occurred between March 29, 2021, and April 1, 2021 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Rocket's gain on sale margins were contracting at the highest rate in two years due to increased competition among mortgage lenders and a shift towards lower margin segments [2]. - It is alleged that Rocket was engaged in a price war with competitors, further compressing margins in its Partner Network operating segment [2]. - The complaint states that adverse trends were accelerating, with gain on sale margins expected to plummet by at least 140 basis points in the first half of 2021 [2]. - The favorable market conditions that previously allowed Rocket to achieve high gain on sale margins had disappeared, returning to levels not seen since Q1 2019 [2]. - The company's gain-on-sale margins had fallen materially below recent historical averages, contradicting positive statements made by the defendants about the company's operations and prospects [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the relevant time frame have until July 8, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the U.S. for seven consecutive years [4].

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. for alleged violations of federal securities laws during the Class Period from April 29, 2025, to June 23, 2025 [1][2]. Group 1: Allegations Against Hims & Hers - The lawsuit claims that Hims & Hers made materially false and misleading statements and failed to disclose adverse facts about its business and operations [3]. - Specific allegations include the deceptive promotion of illegitimate versions of Wegovy® that jeopardized patient safety, risking the termination of its collaboration with Novo Nordisk [3]. - The complaint also states that positive statements made by the company regarding its business prospects were misleading and lacked a reasonable basis [3]. Group 2: Details of Misleading Statements - Allegations include that Hims & Hers misrepresented its communication with Novo Nordisk, suggesting it would ensure continued access to Wegovy for subscribers [4]. - The complaint asserts that Novo approved Hims' offerings of compounded semaglutide products, which were falsely presented as compliant with regulations [4]. - Additionally, it is claimed that Hims & Hers made positive statements about the partnership with Novo and the availability of Wegovy alongside compounded products, which were misleading [4]. Group 3: Next Steps for Investors - Investors who suffered losses in Hims & Hers have until August 25, 2025, to request to be appointed as lead plaintiff in the class action [5]. - The law firm representing the investors operates on a contingency fee basis, meaning they will only collect fees if the case is successful [6].

Core Viewpoint - Altimmune, Inc. is under investigation for potential securities fraud following the release of mixed results from a clinical trial, which led to a significant drop in its stock price [1][2]. Group 1: Investigation and Legal Context - Pomerantz LLP is investigating claims on behalf of investors of Altimmune regarding possible securities fraud or unlawful business practices by the company and its officers or directors [1]. - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud [3]. Group 2: Clinical Trial Results and Market Reaction - On June 26, 2025, Altimmune announced "topline results" from the IMPACT Phase 2b trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH), describing the results as "positive" [2]. - The trial reported fibrosis improvement rates of 31.8% and 34.5% for pemvidutide doses of 1.2 mg and 1.8 mg, respectively, compared to 25.9% for placebo, with the differences not being statistically significant [2]. - Following the announcement, Altimmune's stock price fell by $4.10, or 53.18%, closing at $3.61 per share on the same day [2].

Core Viewpoint - Tesla is under investigation for potential securities fraud and unlawful business practices following the launch of its robotaxi service and subsequent reports of erratic driving behavior by the vehicles [1][2]. Group 1: Investigation and Legal Context - Pomerantz LLP is investigating claims on behalf of Tesla investors regarding possible securities fraud or unlawful business practices by the company and its officers [1]. - The investigation was prompted by the U.S. National Highway Traffic Safety Administration contacting Tesla after reports of robotaxis driving erratically and violating traffic laws [2]. Group 2: Impact on Stock and Investor Sentiment - Following the news of the NHTSA investigation, Tesla's stock price experienced a significant decline, negatively affecting investors [2].

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. concerning allegations of securities fraud and unlawful business practices [2][3]. Group 1: Lawsuit Details - The lawsuit involves claims that Hims & Hers and certain officers/directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Hims & Hers securities during the Class Period have until August 25, 2025, to request to be appointed as Lead Plaintiff [3]. Group 2: Partnership and Stock Impact - On April 29, 2025, Hims & Hers announced a collaboration with Novo Nordisk to sell a bundled offering of Wegovy® [3]. - On June 23, 2025, Novo Nordisk terminated its partnership with Hims & Hers, citing deceptive promotion and selling of illegitimate versions of Wegovy® that jeopardized patient safety [3]. - Following the termination announcement, Hims & Hers' stock price dropped by $22.24, or 34.63%, closing at $41.98 per share [3].

Group 1 - Edgewise Therapeutics is under investigation for potential securities fraud or unlawful business practices involving its officers and/or directors [1] - The company reported clinical trial data for its lead asset, sevasemten, indicating "positive" results for Becker and Duchenne muscular dystrophies, but the FDA deemed the data insufficient for accelerated approval [2] - Following the announcement, Edgewise's stock price decreased by $1.27 per share, or 8.86%, closing at $14.33 per share [3] Group 2 - Pomerantz LLP is a prominent firm specializing in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - A class action lawsuit has been filed against Tempus AI, Inc. regarding allegations of securities fraud and unlawful business practices [2][3]. Group 1: Lawsuit Details - The lawsuit involves claims that Tempus and certain officers and directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Tempus securities during the Class Period have until August 12, 2025, to request to be appointed as Lead Plaintiff [3]. Group 2: Concerns Raised - A report by Spruce Point Capital Management on May 28, 2025, raised concerns about Tempus, including aggressive accounting and financial reporting practices [3]. - The report also highlighted that several members of Tempus's Board and executives have been associated with companies that restated financial results [3]. - Key strategic partnerships and deal announcements with AstraZeneca and Pathos AI are under scrutiny according to the report [3]. Group 3: Company Background - Pomerantz LLP, the firm handling the lawsuit, is recognized for its expertise in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for class members [4].

NEW YORK, June 27, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Open Lending Corporation (NASDAQ: LPRO) between February 24, 2022 and March 31, 2025, both dates inclusive (the "Class Period"), of the important June 30, 2025 lead plaintiff deadline.So what: If you purchased Open Lending securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangemen ...

SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Open Lending Corporation (NASDAQ: LPRO) securities between February 24, 2022 and March 31, 2025, both dates inclusive (the “Class Period”), have until this upcoming Monday, June 30, 2025 to seek appointment as lead plaintiff of the Open Lending class action lawsuit. Captioned Bradley v. Open Lending Corporation, No. 25-cv-00650 (W.D. Tex.), the Open Lending class action lawsuit charges Ope ...

Core Viewpoint - Iovance Biotherapeutics Inc. is undergoing a leadership transition with the resignation of CFO Jean-Marc Bellemin amid commercial challenges and a class-action lawsuit related to its flagship drug Amtagvi [1][2][3]. Group 1: Leadership Transition - CFO Jean-Marc Bellemin will resign effective July 10, 2025, to pursue other endeavors, having held the position since November 2020 [1][2]. - The company has not yet named a successor for the CFO role, creating uncertainty during a challenging period [2]. Group 2: Commercial Challenges - Iovance's first-quarter sales for Amtagvi significantly underperformed expectations, leading to a revision of full-year revenue projections [3]. - The company attributed its disappointing results to "recent launch dynamics," including slow treatment timelines and higher-than-expected patient drop-off rates [6]. Group 3: Legal Issues - Iovance is facing a class-action lawsuit alleging securities fraud related to its portrayal of authorized treatment centers (ATCs) that are essential for administering Amtagvi [4][5]. - The lawsuit claims that the company misrepresented the operational efficiency of ATCs, which were reportedly experiencing delays and inefficiencies [5]. Group 4: Market Reaction - Following the disclosure of underwhelming first-quarter results and revised revenue guidance, Iovance's stock fell over 44%, from $3.17 to $1.75 per share within a day [7].